Highlights
- CHM has initiated enrolment of newly diagnosed, older, or unfit AML patients in its ADVENT-AML Phase 1B clinical trial.
- Dose escalation phase of the study has been completed with no unexpected safety concerns or dose-limiting toxicities observed.
- The trial is being conducted at MD Anderson Cancer Center and will enrol up to 20 newly diagnosed AML patients unsuitable for intensive chemotherapy or stem cell transplant.
Chimeric Therapeutics Limited (ASX:CHM), an Australian cell therapy company, has advanced its ADVENT-AML Phase 1B clinical trial to include newly diagnosed AML patients who are older or otherwise unfit for treatments such as chemotherapy or allogeneic stem cell transplantation and have not received prior AML treatment.
The dose expansion phase of the study aims to enrol up to 20 patients.
About the trial
Enrolment of relapsed/refractory AML patients has been completed in the dose finding portion of the Phase 1B trial, and it was successfully completed. This portion of the study involved six patients, with the treatment showing no signs of dose-limiting toxicities or unexpected safety issues.
CHM shares were trading at AU$0.006 per share at the time of writing on 16 December 2024.